Finding the Best Stocks to Buy on Wall Street
Blue Chip Growth Beats the Market Again
Before I get to the details, I first want to report how well our Blue Chip Growth Letter has done for the first half of the year. According to The Hulbert Financial Digest, which is an independent tracker of investment newsletters, our Blue Chip Growth Buy List beat the rest of the market by a full 10% for the first six months of 2008.
I'm afraid I have bad news for the folks who still believe in an "efficient market." Blue Chip Growth is on its way toward beating the market for the ninth time in the last 11 years! For the last 10-1/2 years, our Buy List has gained 267.2% compared with just 56.4% for the S&P 500. That means we've lapped the market more than four times, and we're closing in on the fifth! Clearly, we know the best stocks to buy!
We have a lot of ground to cover in this issue, and I'll get right to it in a moment. But first, I want to let you know that now's your chance to get a full year of Blue Chip Growth for $149. That's 12 issues, plus 52 weekly hotlines. You'll also have complete access to our earnings service, our Buy List, and of course, our legendary Blue Chip Growth Buy List.
One more thing, if you sign up today, I'll include my latest report "How to Invest $50,000 Right Now." This is a great report for new investors, or experienced investors looking for more specific portfolio guidance. The report normally costs $49, but it's free for all new subscribers. And as always, you get my exclusive money-back guarantee. If you don't like Blue Chip Growth for any reason, you can cancel within the first six months and get a full refund. No questions asked. So join us today!
Other recent e-letter issues:
11.20.08: Automakers Left Empty-Handed
11.13.08: Four Tips for Buying Stocks in Bad Times
11.06.08: The Bull Market for Fundamentals
10.30.08: Why You Should Be Buying Right Now
10.23.08: How to Invest in a Volatile Market
![]() |
- Market Insights: Four Tips for Buying Stocks in Bad Times
- Investor Insights: XTL Biopharmaceuticals Plunges
- Stock Insight: Three Supercharged Stocks
- Blog: The Fed Needs to Cut Rates NOW
- Q&A: Given the global rate cuts, aren't we likely to see further strength in the dollar, which will drag down our energy commodity stocks?
- Top Story: Disaster at Citi
Subscribers log in below for complete portfolios, specific buy prices, up-to-the minute buy/sell/hold recommendations and more! Not a subscriber? Sign up risk-free today.
| Video Demo |
| Stock | Symbol | Grade | |
|---|---|---|---|
| BP PLC (ADS) | BP | C | HOLD |
| Chevron Corp. | CVX | A | BUY |
| ConocoPhillips | COP | B | BUY |
| Exxon Mobil Co | XOM | A | BUY |
| Occidental Pet | OXY | A | BUY |
| Transocean Inc | RIG | B | BUY |
| Stock | Symbol | Grade | |
|---|---|---|---|
| Abbott Laborat | ABT | A | BUY |
| Amgen Inc. | AMGN | A | BUY |
| Covidien Ltd. | COV | A | BUY |
| Genentech Inc. | DNA | A | BUY |
| Icon PLC (ADS) | ICLR | C | HOLD |
| Thoratec Corp. | THOR | A | BUY |









